Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high‐performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry
- 13 August 2002
- journal article
- clinical trial
- Published by Wiley in Journal of Mass Spectrometry
- Vol. 37 (9) , 992-1000
- https://doi.org/10.1002/jms.362
Abstract
Kahalalide F (KF) is a novel cyclic depsipeptide anticancer drug, which has shown anticancer activity both in vitro and in vivo especially against human prostate cancer cell lines. To characterize the pharmacokinetics of KF during a phase I clinical trial in patients with androgen refractory prostate cancer, a method was developed and validated for the quantitative analysis of KF in human plasma using high‐performance liquid chromatography (HPLC) coupled to positive electrospray ionization tandem mass spectrometry (ESI‐MS/MS). Microbore reversed‐phase liquid chromatography (LC) performed with mobile phases containing trifluoroacetic acid, an additive commonly used for separating peptides, resulted in substantial suppression of the signal for KF on ESI‐MS/MS. An alternative approach employing a basic mobile phase provided an excellent response for KF when detected in the positive ion mode. Plasma samples were prepared for LC MS/MS by solid‐phase extraction on C18 cartridges. The LC separation was performed on a Zorbax Extend C18 column (150 × 2.1 mm i.d., particle size 5 µm) with acetonitrile –10 mM aqueous ammonia (85 : 15, v/v) as the mobile phase, at a flow‐rate of 0.20 ml min−1. A butyric acid analogue of KF was used as the internal standard. The lower limit of quantitation (LLQ) using a 500 µl sample volume was 1 ng ml−1 and the linear dynamic range extended to 1000 ng ml−1. The inter‐assay accuracy of the assay was −15.1% at the LLQ and between −2.68 and −9.05% for quality control solutions ranging in concentration from 2.24 to 715 ng ml−1. The inter‐assay precision was 9.91% or better at these concentrations. The analyte was stable in plasma under all relevant conditions evaluated and for a period of 16 h after reconstituting plasma extracts for LC analysis at ambient temperature. Copyright © 2002 John Wiley & Sons, Ltd.Keywords
This publication has 22 references indexed in Scilit:
- DEVELOPMENT OF AN HPLC METHOD WITH UV DETECTION FOR THE PHARMACEUTICAL QUALITY CONTROL OF THE NOVEL MARINE ANTICANCER AGENT KAHALALIDE FJournal of Liquid Chromatography & Related Technologies, 2001
- Development of a Lyophilized Parenteral Pharmaceutical Formulation of the Investigational Polypeptide Marine Anticancer Agent Kahalalide FDrug Development and Industrial Pharmacy, 2001
- Investigation of the Electrospray Plume by Laser-Induced Fluorescence SpectroscopyAnalytical Chemistry, 1999
- Enhanced sensitivity for peptide mapping with electrospray liquid chromatography-mass spectrometry in the presence of signal suppression due to trifluoroacetic acid-containing mobile phasesJournal of Chromatography A, 1995
- Acidity Determination in Droplets Formed by Electrospraying Methanol-Water SolutionsAnalytical Chemistry, 1994
- Kahalalide F: a bioactive depsipeptide from the sacoglossan mollusk Elysia rufescens and the green alga Bryopsis spJournal of the American Chemical Society, 1993
- Electrospray analysis of proteins: A comparison of positive‐ion and negative‐ion mass spectra at high and low pHJournal of Mass Spectrometry, 1992
- Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic StudiesJournal of Pharmaceutical Sciences, 1992
- The structural identification of drug metabolites using thermospray liquid chromatography/mass spectrometryJournal of Mass Spectrometry, 1989
- High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samplesAnalytical Chemistry, 1986